Biotech and Pharmaceuticals Medicine

  • Dec 2- A promising but risky new group of customized cancer drugs will be in focus this weekend at the annual meeting of the American Society of Hematology, where clinical trial results will help clarify their potential for doctors and investors. "Juno has dug themselves into such a deep hole," said Brad Loncar, manager of the Loncar Cancer Immunotherapy ETF.

  • Dec 2- A promising but risky new group of customized cancer drugs will be in focus this weekend at the annual meeting of the American Society of Hematology, where clinical trial results will help clarify their potential for doctors and investors. "Juno has dug themselves into such a deep hole," said Brad Loncar, manager of the Loncar Cancer Immunotherapy ETF.

  • Jardiance, a once-daily pill also known as empagliflozin, was approved by the FDA in 2014 to help lower blood sugar in patients with type 2 diabetes. At the time of approval the FDA asked that a separate trial be conducted to show the drug did not increase the risk of cardiovascular problems. Jardiance belongs to a new family of treatments called SGLT2 inhibitors...

  • Dec 2- The U. S Food and Drug Administration said on Friday it would allow Eli Lilly and Co to state that its diabetes drug Jardiance reduces the risk of death from heart problems, potentially boosting the drug's sales. Jardiance, also known as empagliflozin, was approved by the FDA in 2014 to help lower blood sugar in patients with type 2 diabetes.

  • Dec 2- The U. S Food and Drug Administration said on Friday it had approved Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc's drug, Jardiance, to reduce the risk of cardiovascular death in patients with type 2 diabetes. The risk of death from heart disease is 70 percent higher in diabetics compared to those without diabetes, according to the U.S....

  • BRIEF-GSK APPLIES FOR EU MARKETING NOD FOR COPD DRUG COCKTAIL@. *Gsk files regulatory submission in european union for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD. *Regulatory submissions of closed triple therapy for COPD are anticipated in rest of world beginning in 2017.

  • BRIEF-GSK'S LUNG DRUG GAINS APPROVAL IN JAPAN@. *Relvar Ellipta 100/ 25 mcg gains approval in Japan for use in patients with COPD. *Relvar Ellipta has been approved in Japan for treatment of asthma since 2013 in two strengths- 100/ 25 mcg and 200/ 25 mcg.

  • Jill Teeters with her husband, Dave, and son, Aidan

    Scientists are taking a new approach to the riddle of preterm birth, which kills 1 million babies globally each year.

  • Bluebird Bio CEO on new study data: We're getting profound responses

    CNBC's Meg Tirrell speaks with Bluebird Bio CEO Nick Leschly about his company's successful study of its multiple myeloma treatment as well as the election effect on the biotech sector.

  • But when a drug already taken by thousands of people for intestinal conditions appeared to control the monkey version of HIV, it got the attention of the director of the National Institutes of Allergy and Infectious Diseases. Fauci hopped on a plane to Cambridge, Mass., to personally tell Japan's Takeda Pharmaceutical Co's U.S. representatives that their drug...

  • Nov 30- Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin was found comparable with the branded version in a key study. Unlike generic drugs, which are interchangeable with their branded counterparts, biosimilars approved by the U.S. Food and Drug Administration to date are not...

  • Nov 30- Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin met the main goal in a key study. Pfizer tested the safety and effectiveness of the drug, PF-05280014, in combination with chemotherapeutic agent paclitaxel against Herceptin and paclitaxel in previously untreated...

  • Escherichia coli bacteria in a colored electron-scanning micrograph

    Everyone from government to independent foundations are funding microbiome research. Why bacteria's DNA is garnering so much attention.

  • Nov 29- U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis. Humira, considered the world's biggest-selling medicine, generates $15 billion in annual sales and treats rheumatoid...

  • *GSK to start large trials testing protective injection. LONDON, Nov 29- Scientists are taking the battle to prevent HIV to the next level with large-scale trials set to start using injections to protect vulnerable groups such as gay men and women in Africa for at least two months. Some women in trials in Africa, for example, said they were reluctant to have HIV...

  • SEOUL, Nov 29- South Korea will cull 3 percent of its total poultry population to curb an outbreak of bird flu that has hit a number of farms across the nation, its agriculture ministry said on Tuesday. Despite the efforts, Korea's Ministry of Agriculture, Food and Rural Affairs said in a statement on Tuesday that four new cases of H5N6 had been confirmed in central...

  • *Says company had 240 mln euros in cash end-Sept. PARIS, Nov 25- France's Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent for the time being and will seek co-development deals modeled on an agreement struck with AstraZeneca in April. In August Pfizer announced the $14 billion...

  • LONDON, Nov 24- GlaxoSmithKline has started pivotal trials of an experimental anaemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude. GSK's daprodustat, given as a pill, is designed to displace injectable EPO products that are used widely in patients with chronic kidney disease.

  • LONDON, Nov 24- GlaxoSmithKline has started pivotal trials of an experimental anemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude. GSK's daprodustat, given as a pill, is designed to displace injectable EPO products that are used widely in patients with chronic kidney disease.

  • Many investors and families had been counting on solanezumab to become the first approved medicine to slow progression of the disease, which the Alzheimer's Association estimates will strike as many as 28 million Americans by midcentury. Sam Gandy, director of Mount Sinai School of Medicine Center for Cognitive Health, referring to a different protein...